2025 Global Antibodies In Oncology Market Revenue Opportunities Report
Description
The 2025 Global Antibodies In Oncology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies active in the antibodies oncology market globally are Roche, Bristol-Myers Squibb, Merck & Co., and Amgen. Roche leads with a robust oncology pipeline and breakthrough therapies such as Trastuzumab and Tecentriq, generating multi-billion dollar revenues and advancing bispecific antibodies in targeted cancer treatment. Bristol-Myers Squibb, known for its acquisition of Celgene, markets key immuno-oncology drugs including Darzalex for multiple myeloma. Merck & Co. dominates with its blockbuster drug Keytruda, which alone generated over $24 billion in 2023, focusing heavily on bispecific antibodies and immuno-oncology pipelines. Amgen emphasizes recombinant DNA technology and recently expanded through acquisitions, contributing innovative biologics for oncology applications.
These companies lead through extensive R&D investments, large clinical trial portfolios, and strategic global partnerships strengthening their market presence. The U.S. dominates as the key region with high cancer prevalence and supportive regulatory environments, while Asia-Pacific is the fastest-growing market due to rising cancer cases and evolving healthcare infrastructure. All four are deeply involved in advancing antibody modalities such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, driving growth in precision oncology therapies projected to exceed hundreds of billions in market value by 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies active in the antibodies oncology market globally are Roche, Bristol-Myers Squibb, Merck & Co., and Amgen. Roche leads with a robust oncology pipeline and breakthrough therapies such as Trastuzumab and Tecentriq, generating multi-billion dollar revenues and advancing bispecific antibodies in targeted cancer treatment. Bristol-Myers Squibb, known for its acquisition of Celgene, markets key immuno-oncology drugs including Darzalex for multiple myeloma. Merck & Co. dominates with its blockbuster drug Keytruda, which alone generated over $24 billion in 2023, focusing heavily on bispecific antibodies and immuno-oncology pipelines. Amgen emphasizes recombinant DNA technology and recently expanded through acquisitions, contributing innovative biologics for oncology applications.
These companies lead through extensive R&D investments, large clinical trial portfolios, and strategic global partnerships strengthening their market presence. The U.S. dominates as the key region with high cancer prevalence and supportive regulatory environments, while Asia-Pacific is the fastest-growing market due to rising cancer cases and evolving healthcare infrastructure. All four are deeply involved in advancing antibody modalities such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, driving growth in precision oncology therapies projected to exceed hundreds of billions in market value by 2030.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
